Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,495Revenue $M71.9Net Margin (%)-60.1Altman Z-Score15.0
Enterprise Value $M4,337EPS $-0.8Operating Margin %-142.2Piotroski F-Score2
P/E(ttm)--Beneish M-Score4.2Pre-tax Margin (%)-64.0Higher ROA y-yN
Price/Book7.010-y EBITDA Growth Rate %--Quick Ratio4.4Cash flow > EarningsY
Price/Sales42.65-y EBITDA Growth Rate %--Current Ratio4.9Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-9.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-13.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M109ROIC % (ttm)-49.1Gross Margin Increase y-yN

Gurus Latest Trades with XON

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
XONFirst Eagle Investment 2015-03-31 Add$26.08 - $50.16
$ 41.159%Add 4.84%828,104
XONT Boone Pickens 2014-12-31 Buy 0.53%$16.61 - $28.02
$ 41.1579%New holding10,000
XONDavid Einhorn 2014-12-31 Sold Out -0.05%$16.61 - $28.02
$ 41.1579%Sold Out0
XONDavid Einhorn 2014-09-30 Reduce-0.06%$17.86 - $26.59
$ 41.1593%Reduce 47.39%197,278
XONDavid Einhorn 2014-06-30 Reduce-0.39%$15.3 - $25.93
$ 41.1595%Reduce 72.81%375,000
XONFirst Eagle Investment 2014-06-30 Buy 0.04%$15.3 - $25.93
$ 41.1595%New holding661,564
XONDavid Einhorn 2014-03-31 Reduce-0.26%$22.5 - $36.82
$ 41.1543%Reduce 37.58%1,379,014
XONT Boone Pickens 2013-12-31 Sold Out -0.47%$17.65 - $25.5
$ 41.1595%Sold Out0
XONDavid Einhorn 2013-09-30 Buy 0.86%$21.36 - $29.7
$ 41.1570%New holding2,176,868
XONT Boone Pickens 2013-09-30 Buy 0.47%$21.36 - $29.7
$ 41.1570%New holding12,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

XON is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!

XON: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KIRK RANDAL JCEO, 10% Owner 2015-01-27Buy555,556$2752.41view
KIRK RANDAL JCEO, 10% Owner 2014-05-13Buy65,173$15.19170.9view
Lehr Donald P.Chief Legal Officer 2014-05-13Buy1,850$15.99157.35view
Reed Thomas D.Chief Science Officer 2014-05-13Buy640$15.6163.78view
Krishnan SumaSVP--Product Development 2014-05-09Buy20,900$14.21189.58view
Krishnan Krish SCOO 2014-05-09Buy20,900$14.21189.58view
Kasser Thomas R.SVP--Food Sector 2014-05-09Buy10,000$13.39207.32view
Huang KellySVP-Consumer Sector 2014-05-09Buy3,200$15.78160.77view
KIRK RANDAL JCEO, 10% Owner 2014-05-09Buy67,333$15.16171.44view
KIRK RANDAL JCEO, 10% Owner 2014-03-27Buy243,001$25.7259.99view

Press Releases about XON :

    Quarterly/Annual Reports about XON:

    News about XON:

    Articles On GuruFocus.com
    Bill Miller Identifies What Could Be The Stock of The Decade Feb 10 2015 
    5-Year Lows: American Eagle Outfitters, Intrexon Corp, Mack-Cali Realty Corp, and Weight Watchers In Apr 20 2014 
    Daniel Loeb Comments on Intrexon Corporation Jan 22 2014 
    Daniel Loeb Lags S&P But Top New Stocks Advance Jan 07 2014 
    David Einhorn’s New Stocks – TPX, XON, NVR Nov 14 2013 
    Weekly CEO Buys Highlight: XON, ARCP, FSFR, CNTY, RHP Aug 18 2013 

    More From Other Websites
    Intrexon to Present at the Jefferies 2015 Global Healthcare Conference May 26 2015
    Intrexon to Present at the Jefferies 2015 Global Healthcare Conference May 26 2015
    Fibrocell to Present at Jefferies 2015 Global Healthcare Conference May 26 2015
    Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Price Target $7.00 May 21 2015
    INTREXON CORP Financials May 19 2015
    Synthetic Biologics' Novel SYN-010 Preclinical Data Featured in Digestive Disease Week® Poster May 18 2015
    Soligenix Announces First Quarter 2015 Highlights and Financial Results May 14 2015
    Fibrocell Receives Rare Pediatric Disease Designation From FDA for FCX-007 for the Treatment of... May 12 2015
    INTREXON CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits May 12 2015
    5 Drug Stocks Moving On Earnings, Trial Data Late May 11 2015
    IBD Market Wrap - 05/11/15 May 11 2015
    Intrexon tops Street 1Q forecasts May 11 2015
    Intrexon tops Street 1Q forecasts May 11 2015
    Stocks Lower; Gap Flat After Hours As Q1 Disappoints May 11 2015
    Intrexon Announces First Quarter 2015 Financial Results May 11 2015
    INTREXON CORP Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... May 11 2015
    Intrexon Announces First Quarter 2015 Financial Results May 11 2015
    Synthetic Biologics Reports First Quarter 2015 Financial Results and Operational Highlights May 11 2015
    Q1 2015 Intrexon Corp Earnings Release - After Market Close May 11 2015
    Will Higher Expenses Hurt Intrexon (XON) in Q1 Earnings? - Analyst Blog May 08 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)